NCT04226443 is a NA clinical trial of Midazolam intravenous injection in Sedative Adverse Reaction, sponsored by Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital.

Who is sponsoring NCT04226443?

NCT04226443 is sponsored by Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital.

What drugs are being tested in NCT04226443?

Interventions in NCT04226443: Midazolam intravenous injection, Remifentanil intravenous bolus dose.

What condition does NCT04226443 study?

NCT04226443 studies Sedative Adverse Reaction, Analgesic Adverse Reaction, Midazolam Adverse Reaction, Adverse Reaction to Drug, Patient Satisfaction, Chronic Kidney Diseases, Arteriovenous Fistula.

Is NCT04226443 still recruiting?

NCT04226443 is currently completed. Last updated 13 January 2020.

Last reviewed 2020-01-13 · How we verify

NCT04226443

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Use of Midazolam and Remifentanil During Dialysis Access Procedures

Completed NA Last updated 13 January 2020

What this trial tests

NA trial testing Midazolam intravenous injection in Sedative Adverse Reaction in 99 participants. Completed in 30 April 2016.

Timeline

28 August 2012

Primary endpoint
15 April 2016

30 April 2016

Quick facts

Lead sponsor	Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	99
Start date	28 August 2012
Primary completion	15 April 2016
Estimated completion	30 April 2016

Drugs / interventions tested

Midazolam intravenous injection — full drug profile →
Remifentanil intravenous bolus dose — full drug profile →

Conditions studied

Sedative Adverse Reaction — all drugs for Sedative Adverse Reaction →
Analgesic Adverse Reaction — all drugs for Analgesic Adverse Reaction →
Midazolam Adverse Reaction — all drugs for Midazolam Adverse Reaction →
Adverse Reaction to Drug — all drugs for Adverse Reaction to Drug →

Sponsor

Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital

Who can join

Adults 43 to 81, any sex, with Sedative Adverse Reaction or Analgesic Adverse Reaction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

BACKGROUND: Sedation and analgesia are related to unexpected adverse events in chronic renal failure patients undergoing arteriovenous fistula placement procedures under monitored anesthesia care (MAC). OBJECTIVE: Our goal was to investigate and compare the sedation and analgesia related effects and adverse effects of continuous intravenous use of midazolam and intermittent bolus doses of midazolam while intravenous remifentanil is used as a rescue medication in patients with chronic renal failure.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Continuous intravenous versus intermittent bolus midazolam with remifentanil during arteriovenous fistula placement with monitored anesthesia care in chronic renal failure patients: a randomized controlled trial.
Sagiroglu G, Baysal A. · · 2020 · cited 5× · PMID 32493052 · DOI 10.5144/0256-4947.2020.175

Verify or expand the search:

Other recruiting trials for Sedative Adverse Reaction

Currently open trials in the same condition.

NCT06581731 — Comparison of Remifentanil with a Combination of Remimazolam and Dexmedetomidine for Awake Tracheal Intubation · NA · recruiting

Other Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital trials

Trials by the same sponsor.

NCT07467941 — Impact of Visceral Adiposity on Postoperative Atrial Fibrillation After CABG · not yet recruiting
NCT07390903 — GLS in Difficult CPB Weaning · recruiting
NCT06387095 — Efficacy of Parasternal Blocks in Cardiovascular Surgery Patients Undergoing Median Sternotomy · NA · recruiting
NCT06191913 — Microcirculatory Alteration by a Vascular Occlusion Test Using Near-infrared Spectroscopy in Pediatric Cardiac Surgery · completed
NCT03806504 — High PEEP Application Following Pulmonary Thromboendarterectomy; Does it Have Any Impact on Outcome? · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04226443 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
Last refreshed: 13 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04226443.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing